FindTrial
Sign In

DC1 vaccine

BIOLOGICAL2 trials

Sponsors

Roswell Park Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute

Conditions

Breast Cancer FemaleBreast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIBreast Cancer, MaleCancer of ProstateCancer of the ProstateHER2 Positive Breast Carcinoma

Phase 2

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
CompletedNCT00970203
Roswell Park Cancer InstituteCancer of Prostate, Cancer of the Prostate, Neoplasms, Prostate +4
Start: 2009-09-30End: 2019-10-05Updated: 2020-11-03
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Active, not recruitingNCT03384914
H. Lee Moffitt Cancer Center and Research InstituteBreast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I +5
Start: 2018-02-19End: 2027-12-01Updated: 2026-03-06

Related Papers

Abstract PS3-10-26: Long-term outcomes of two her2 vaccines to prevent recurrence in patients with her-2 positive early stage breast cancer
Clinical Cancer Research2026-02-17
BSLM-07 A FIRST IN HUMAN PHASE 1 TRIAL OF DOSE ESCALATING INTRATHECAL (IT) DENDRITIC CELLS (CDC1S) PRIMED AGAINST HER2/HER3 IN PATIENTS (PTS) WITH LEPTOMENINGEAL DISEASE (LMD) FROM TRIPLE NEGATIVE (TNBC) OR HER2+ BREAST CANCER (BC)
Neuro-Oncology Advances2024-08-011 citations
A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).
Journal of Clinical Oncology2024-06-011 citations
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.
Journal of Clinical Oncology2023-06-013 citations
Abstract OT1-16-01: A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer
Cancer Research2022-02-151 citations